T

Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM

Watchlist Manager
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Watchlist
Price: 3 209.8501 INR -0.49% Market Closed
Market Cap: 1.1T INR
Have any thoughts about
Torrent Pharmaceuticals Ltd?
Write Note

Torrent Pharmaceuticals Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Torrent Pharmaceuticals Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Equity
â‚ą75B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
12%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Equity
â‚ą282.5B
CAGR 3-Years
17%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Equity
â‚ą283.6B
CAGR 3-Years
13%
CAGR 5-Years
13%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Equity
â‚ą691.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
12%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Total Equity
â‚ą198.3B
CAGR 3-Years
15%
CAGR 5-Years
14%
CAGR 10-Years
19%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Equity
â‚ą93.6B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Torrent Pharmaceuticals Ltd
Glance View

Market Cap
1.1T INR
Industry
Pharmaceuticals
Economic Moat
Narrow

Torrent Pharmaceuticals Ltd. has steadily carved a niche for itself as a formidable player in the global pharmaceutical landscape. Founded in 1959 in India, the company specializes in developing, manufacturing, and marketing a diverse portfolio of generic and branded formulations across therapeutic areas such as cardiovascular, central nervous system, and diabetology, among others. With a robust presence in over 40 countries and a strong focus on research and development, Torrent has established partnerships and collaborations that bolster its ability to innovate and expand its product offerings. The company’s commitment to quality and regulatory compliance is evident as it operates multiple state-of-the-art manufacturing facilities certified by global regulatory bodies, ensuring that their products meet the highest international standards. For investors, Torrent Pharmaceuticals presents a compelling opportunity characterized by steady growth and a focus on long-term value creation. In recent years, the company has demonstrated resilience despite market challenges, driven by a growing demand for affordable medicines and its strategic focus on expanding its international footprint, particularly in regulated markets. The firm’s robust pipeline of products, coupled with its strengths in key therapeutic segments, positions it well for future growth. Furthermore, Torrent’s consistent financial performance and prudent management practices reflect the core principles of value investing, making it an attractive consideration for those looking to invest in a company that not only prioritizes profitability but also contributes positively to global healthcare outcomes. As the pharmaceutical industry continues to evolve, Torrent Pharmaceuticals Ltd. stands ready to navigate the complexities ahead while delivering sustained shareholder value.

TORNTPHARM Intrinsic Value
1 953.2021 INR
Overvaluation 39%
Intrinsic Value
Price
T

See Also

What is Torrent Pharmaceuticals Ltd's Total Equity?
Total Equity
75B INR

Based on the financial report for Sep 30, 2024, Torrent Pharmaceuticals Ltd's Total Equity amounts to 75B INR.

What is Torrent Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
12%

Over the last year, the Total Equity growth was 12%. The average annual Total Equity growth rates for Torrent Pharmaceuticals Ltd have been 6% over the past three years , 8% over the past five years , and 12% over the past ten years .

Back to Top